ABLINK

ABLINK (Chengdu ABLINK Biotechnology Co., Ltd.) is a technology-driven company that utilizes leading fully synthetic library technologies to drive the discovery and optimization of macromolecular drugs. Starting with a "300-billion-level diversity" biopharmaceutical library developed through phage display and mammalian cell display technologies, and based on self-collected, continuously generated, high-quality, high-quantity, verified, and real drug R&D data, ABLINK is committed to creating a novel AI application workflow driven by both data and biology. The company aims to establish a "dry and wet combined" macromolecular AI drug R&D platform to drastically shorten the development cycle of macromolecular drugs and realize the ideal of discovering and creating macromolecular drugs with infinite diversity and boundless potential.